GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
Clinical Cancer Research, 06/12/2012
Wallin JJ et al. – GDC–0941 augments the efficacy of docetaxel by increasing drug–induced apoptosis in breast cancer models.



